SeaStar Medical Reports First Successful Treatment of Pediatric Patient with Hemophagocytic Lymphohistiocytosis (HLH) and Multi-Organ Failure with its SCD
Case report published in peer-reviewed journal, Pediatric Nephrology...
LMF Acquisition Opportunities, Inc. Announces Extension of Deadline to Complete Business Combination
TAMPA, FL, July 29, 2022 (GLOBE NEWSWIRE) -- LMF Acquisition Opportunities, Inc. (NASDAQ: LMAO) (the “Company”) announced today that its board of...
SeaStar Medical Submits Humanitarian Device Exemption Application to FDA for Use of Selective Cytopheretic Device in Children with Acute Kidney Injury
Application follows successful pilot study demonstrating the SCD was safe with probable clinical benefits for pediatric patients...
SeaStar Medical Announces Publication of Clinical Trial Results Demonstrating its SCD Significantly Lowered Mortality Rates among Critically Ill ICU COVID-19 Patients by Safely and Effectively Stopping Inflammation Causing Cytokine Storms
Results published in the Society of Critical Care Management’s journal, Critical Care Explorations...